Browsing by Author "Eisenstein, Eric L"
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
Item Open Access 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines(Circulation) Thompson, Annemarie; Fleischmann, Kirsten E; Smilowitz, Nathaniel R; de Las Fuentes, Lisa; Mukherjee, Debabrata; Aggarwal, Niti R; Ahmad, Faraz S; Allen, Robert B; Altin, S Elissa; Auerbach, Andrew; Berger, Jeffrey S; Chow, Benjamin; Dakik, Habib A; Eisenstein, Eric L; Gerhard-Herman, Marie; Ghadimi, Kamrouz; Kachulis, Bessie; Leclerc, Jacinthe; Lee, Christopher S; Macaulay, Tracy E; Mates, Gail; Merli, Geno J; Parwani, Purvi; Poole, Jeanne E; Rich, Michael W; Ruetzler, Kurt; Stain, Steven C; Sweitzer, BobbieJean; Talbot, Amy W; Vallabhajosyula, Saraschandra; Whittle, John; Williams, Kim Allan; Peer Review Committee MembersAim: The “2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery” provides recommendations to guide clinicians in the perioperative cardiovascular evaluation and management of adult patients undergoing noncardiac surgery. Methods: A comprehensive literature search was conducted from August 2022 to March 2023 to identify clinical studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Structure: Recommendations from the “2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery” have been updated with new evidence consolidated to guide clinicians; clinicians should be advised this guideline supersedes the previously published 2014 guideline. In addition, evidence-based management strategies, including pharmacological therapies, perioperative monitoring, and devices, for cardiovascular disease and associated medical conditions, have been developed.Item Open Access 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.(Journal of the American College of Cardiology, 2024-09) Writing Committee Members; Thompson, Annemarie; Fleischmann, Kirsten E; Smilowitz, Nathaniel R; de Las Fuentes, Lisa; Mukherjee, Debabrata; Aggarwal, Niti R; Ahmad, Faraz S; Allen, Robert B; Altin, S Elissa; Auerbach, Andrew; Berger, Jeffrey S; Chow, Benjamin; Dakik, Habib A; Eisenstein, Eric L; Gerhard-Herman, Marie; Ghadimi, Kamrouz; Kachulis, Bessie; Leclerc, Jacinthe; Lee, Christopher S; Macaulay, Tracy E; Mates, Gail; Merli, Geno J; Parwani, Purvi; Poole, Jeanne E; Rich, Michael W; Ruetzler, Kurt; Stain, Steven C; Sweitzer, BobbieJean; Talbot, Amy W; Vallabhajosyula, Saraschandra; Whittle, John; Williams, Kim AllanAim
The "2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery" provides recommendations to guide clinicians in the perioperative cardiovascular evaluation and management of adult patients undergoing noncardiac surgery.Methods
A comprehensive literature search was conducted from August 2022 to March 2023 to identify clinical studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline.Structure
Recommendations from the "2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery" have been updated with new evidence consolidated to guide clinicians; clinicians should be advised this guideline supersedes the previously published 2014 guideline. In addition, evidence-based management strategies, including pharmacological therapies, perioperative monitoring, and devices, for cardiovascular disease and associated medical conditions, have been developed.Item Open Access Steps to Health employee weight management randomized control trial: short-term follow-up results.(J Occup Environ Med, 2015-02) Østbye, Truls; Stroo, Marissa; Brouwer, Rebecca JN; Peterson, Bercedis L; Eisenstein, Eric L; Fuemmeler, Bernard F; Joyner, Julie; Gulley, Libby; Dement, John MOBJECTIVE: To present the short-term follow-up findings of the Steps to Health study, a randomized trial to evaluate the effectiveness of two employee weight management programs offered within Duke University and the Health System. METHODS: A total of 550 obese (body mass index, ≥30 kg/m2) employees were randomized 1:1 between January 2011 and June 2012 to the education-based Weight Management (WM) or the WM+ arm, which focused on behavior modification. Employees were contacted to complete a follow-up visit approximately 14 months after baseline. RESULTS: There were no clinically, or statistically, meaningful differences between arms, but there were modest reductions in body mass index, and positive, meaningful changes in diet and physical activity for both arms. CONCLUSIONS: The modest positive effects observed in this study may suggest that to achieve weight loss through the workplace more intensive interventions may be required.Item Open Access Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.(J Cardiovasc Pharmacol, 2015-05) Mentz, Robert J; Buggey, Jonathan; Fiuzat, Mona; Ersbøll, Mads K; Schulte, Phillip J; DeVore, Adam D; Eisenstein, Eric L; Anstrom, Kevin J; OʼConnor, Christopher M; Velazquez, Eric JFurosemide has historically been the primary loop diuretic in heart failure patients despite data suggesting potential advantages with torsemide. We used the Duke Echocardiography Lab Database to investigate patients admitted with heart failure to Duke Hospital from 2000 to 2010 who were discharged on either torsemide or furosemide. We described baseline characteristics based on discharge diuretic and assessed the relationship with all-cause mortality through 5 years. Of 4580 patients, 86% (n = 3955) received furosemide and 14% (n = 625) received torsemide. Patients receiving torsemide were more likely to be female and had more comorbidities compared with furosemide-treated patients. Survival was worse in torsemide-treated patients [5-year Kaplan-Meier estimated survival of 41.4% (95% CI: 36.7-46.0) vs. 51.5% (95% CI: 49.8-53.1)]. After risk adjustment, torsemide use was no longer associated with increased mortality (hazard ratio 1.16; 95% CI: 0.98-1.38; P = 0.0864). Prospective trials are needed to investigate the effect of torsemide versus furosemide because of the potential for residual confounding.